SNMMI: Phillip Kuo discusses Alzheimer’s disease imaging and treatment

May 31, 2026

LOS ANGELES – In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, brain imaging expert Phillip Kuo, MD, PhD, discussed developments in diagnosing and treating Alzheimer’s disease, including the impact that new tau radiotracers may have in the field.

Check out AuntMinnie’s full coverage of SNMMI 2026 on our ShowCast.

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

Early FAPI-PET scans match 60-minute scans for lung cancer staging

June 10, 2026

PET reveals brain receptor deficits in schizophrenia

June 4, 2026

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

AI-driven cardiac PET attenuation correction shows promise

June 3, 2026

Representative SV2A PET images comparing synaptic density in healthy and disease states. The left panel shows F-18 SynVesT-1 PET distribution volume (VT) maps of the brain and spinal cord in a naïve control mouse and a mouse with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The right panel shows Cu-11 UCB-J PET images of the brain of a 46-year-old male healthy control (left) and 43-year-old female MS patient (right).

SNMMI: PET reveals new brain activity in multiple sclerosis

June 2, 2026

Early FAPI-PET scans match 60-minute scans for lung cancer staging

By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.

June 10, 2026

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

PET reveals brain receptor deficits in schizophrenia

The study confirms that deficits in M1 receptor are present in a subgroup of schizophrenia patients.

June 4, 2026

AI-driven cardiac PET attenuation correction shows promise

By Kate Madden Yee

The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.

June 3, 2026

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

SNMMI: PET reveals new brain activity in multiple sclerosis

Understanding how and where certain brain connections are lost can help explain the symptoms patients experience.

June 2, 2026

Representative SV2A PET images comparing synaptic density in healthy and disease states. The left panel shows F-18 SynVesT-1 PET distribution volume (VT) maps of the brain and spinal cord in a naïve control mouse and a mouse with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The right panel shows Cu-11 UCB-J PET images of the brain of a 46-year-old male healthy control (left) and 43-year-old female MS patient (right).

SNMMI: New PET platform guides real-time bone cancer margin assessment

By Kate Madden Yee

The approach has the potential to reshape surgical practice for osteosarcoma by allowing for precise tumor resection.

June 2, 2026

(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.

SNMMI names officers for 2026–2027 term

By AuntMinnie.com staff writers

Society of Nuclear Medicine and Molecular Imaging leaders take office.

June 2, 2026

Snmmi Thumb 3m Ipa Ljl Nl

SNMMI: Incoming president talks meeting highlights, previews next year

By Kate Madden Yee

AuntMinnie.com interviewed incoming SNMMI president Heather Jacene, MD.

June 2, 2026

Heather Jacene, MD

SNMMI: Biomarkers predict I-131 response in obese thyroid cancer patients

By Kate Madden Yee

Metabolic status should be considered in post-therapy evaluation of obese differentiated thyroid cancer patients, researchers noted.

June 2, 2026

SNMMI: Theranostic approach may treat PSMA-negative prostate cancer

By Amerigo Allegretto

A theranostic approach could help improve PET imaging for neuroendocrine prostate cancer care.

June 2, 2026

RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.

SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma

Researchers aim for "more precise molecular map" for kidney cancer.

June 1, 2026

A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.

SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater

By Kate Madden Yee

An increase in the use of radionuclide therapy has added burden to wastewater management systems.

June 1, 2026

SNMMI honors Vasken Dilsizian with two distinctions at 2026 meeting

By AuntMinnie.com staff writers

Vasken Dilsizian, MD, has received the Wagner Lectureship and the Minoshima-Pappas Transformational Leadership Award.

June 1, 2026

Vasken Dilsizian, MD

Page 1 of 3